Jove
Visualize
联系我们

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Hazard Ratio01:12

Hazard Ratio

69
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
69
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

37
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
37
Relative Risk01:12

Relative Risk

93
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
93

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Quantitative Estimation of Clinical Intrasubject Variability of a Pharmacokinetic Parameter.

The AAPS journal·2026
Same author

Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Some Common Dose-Exposure-Response Estimands and Conditions for Their Causal Identifiability.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Latent Variable Indirect Response Modeling of Cendakimab Exposure-Response for Longitudinal Dysphagia Days Using a Combined Uniform-Binomial Likelihood Framework.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B.

Clinical pharmacokinetics·2025
Same author

Operating Characteristics of the Simulated Healthy Participant Approach in Impaired Clearance Studies.

The AAPS journal·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: May 13, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

综合安全暴露-反应分析,以支持Ritlecitinib剂量选择.

Yeamin Huh1, Ruolun Qiu2, John Prybylski1

  • 1Pfizer Research and Development, Pfizer Inc, Groton, Connecticut, USA.

CPT: pharmacometrics & systems pharmacology
|May 12, 2025
PubMed
概括
此摘要是机器生成的。

里特利西替尼 (Ritlecitinib) 显示出适合治疗白发症 (AA) 的安全性. 暴露-反应分析证实QTc延长和淋巴缺血的风险最小,支持成人和青少年的50mg非负载剂量.

关键词:
建模和模拟的模型和模拟.药物动力学 - 药物动力学人口分析 人口分析

更多相关视频

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
08:46

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

2.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

相关实验视频

Last Updated: May 13, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications
08:46

Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications

Published on: April 21, 2022

2.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 临床安全 临床安全
  • 药物开发 药物开发

背景情况:

  • 作为一种激酶抑制剂的利特利西替尼 (Ritlecitinib) 已被批准用于治疗白发性脱发症 (AA).
  • 关键的2b/3期研究评估了各种剂量方案.
  • 了解安全性概况对于最佳剂量选择至关重要.

研究的目的:

  • 用暴露-反应 (ER) 分析来描述利西提尼布的安全性.
  • 为了告知成人和青少年对AA治疗的剂量选择.
  • 评估不同患者亚组的潜在安全风险.

主要方法:

  • 开发了一个度-QTc模型来评估心脏安全性.
  • 用了一种半机械的PK/PD模型来分析淋巴细胞形状.
  • 采用波桑回归来分析基于暴露的不良事件发生率 (感染,皮疹).

主要成果:

  • 没有证据表明利西提尼布诱导的QTc延长.
  • 里特利西替尼 (Ritlecitinib) 显示了淋巴细胞的边际减少,预测的3/4级淋巴缺血率较低,除了随着加载剂量轻微增加外.
  • 感染和皮疹的发病率增加是剂量依赖的,但在研究范围内不成比例地大.

结论:

  • 里特利西替尼的安全ER关系在包括青少年在内的各个患者亚组中是一致的.
  • 在青少年患者中没有发现独特的安全风险.
  • 综合安全ER分析支持AA患者的50mg非负载剂量治疗方案.